Jazz Pharmaceuticals, AbCellera Ink Up To $876M Cancer Treatment Pact
JAZZ has more than doubled off its 52-week low of $105.
Summary
Jazz Pharmaceuticals and AbCellera have entered into a collaboration agreement valued at up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors. This pact includes preclinical research, options, and licensing of T-cell engaging multispecific antibodies, with AbCellera conducting early-stage research for initial programs. This strategic partnership significantly bolsters Jazz's oncology pipeline, especially following the recent failure of its Zepzelca drug in a Phase 3 trial. AbCellera is committed to initiating a third program within 12 months.
At the time of this announcement, JAZZ was trading at $226.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3B. The 52-week trading range was $105.00 to $243.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.